Detouring of cisplatin to access mitochondrial genome for overcoming resistance

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 29, 2014, Pages 10444-10449

  Marrache, Sean ^a   Pathak, Rakesh K ^a   Dhar, Shanta ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Brain cancer; Click chemistry; OXPHOS; Pharmacokinetics

Indexed keywords

BIOMATERIAL; CISPLATIN; MACROGOL; METHYLTRIPHENYLPHOSPHONIUM; MITOCHONDRIAL DNA; NANOPARTICLE; PLATIN M; POLY(LACTIC CO GLYCOLIC ACID) BLOCK POLYETHYLENEGLYCOL; POLYGLACTIN; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG RELEASE; DRUG TARGETING; EXCISION REPAIR; MALE; MITOCHONDRIAL GENOME; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; RAT; RECOMMENDED DRUG DOSE;

BRAIN CANCER; CLICK CHEMISTRY; OXPHOS; PHARMACOKINETICS;

ANIMALS; BRAIN; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENERGY METABOLISM; GENOME, MITOCHONDRIAL; LACTIC ACID; MALE; MITOCHONDRIA; NANOPARTICLES; NEUROBLASTOMA; ORGAN SPECIFICITY; POLYGLYCOLIC ACID; PRODRUGS; RATS; TISSUE DISTRIBUTION;

EID: 84904640080     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1405244111     Document Type: Article

References (20)

1. Smiraglia DJ, Kulawiec M, Bistulfi GL, Gupta SG, Singh KK (2008) A novel role for mitochondria in regulating epigenetic modification in the nucleus. Cancer Biol Ther 7(8):1182-1190.
2. Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99(9):2467-2498.
3. Damia G, Imperatori L, Stefanini M, D'Incalci M (1996) Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int J Cancer 66(6):779-783. (Pubitemid 26197946)
4. Yang Z, et al. (2006) Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: Possible role in apoptosis. Clin Cancer Res 12(19):5817-5825. (Pubitemid 44629614)
5. Marrache S, Dhar S (2012) Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc Natl Acad Sci USA 109(40):16288-16293.
6. Marrache S, Tundup S, Harn DA, Dhar S (2013) Ex vivo programming of dendritic cells by mitochondria-targeted nanoparticles to produce interferon-gamma for cancer immunotherapy. ACS Nano 7(8):7392-7402.
7. Wisnovsky SP, et al. (2013) Targeting mitochondrial DNA with a platinum-based anticancer agent. Chem Biol 20(11):1323-1328.
8. Pathak RK, Marrache S, Choi JH, Berding TB, Dhar S (2014) The prodrug platin-A: Simultaneous release of cisplatin and aspirin. Angew Chem Int Ed Engl 53(7): 1963-1967.
9. Summerhayes IC, et al. (1982) Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells. Proc Natl Acad Sci USA 79(17):5292-5296. (Pubitemid 12002199)
10. Pathak RK, McNitt CD, Popik VV, Dhar S (2014) Copper-free click-chemistry platform to functionalize Cisplatin prodrugs. Chem Eur J 20(23):6861-6865.
11. Peer D, et al. (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751-760. (Pubitemid 350223348)
12. Reily C, et al. (2013) Mitochondrially targeted compounds and their impact on cellular bioenergetics. Redox Biol 1(1):86-93.
13. dos Santos WL, Rahman J, Klein N, Male DK (1996) Control of lymphocyte adhesion to brain and aortic endothelium: ICAM-1, VCAM-1 and negative charge. J Neuroimmunol 66(1-2):125-134. (Pubitemid 26193118)
14. Oldendorf WH, Cornford ME, Brown WJ (1977) The large apparent work capability of the blood-brain barrier: A study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann Neurol 1(5):409-417.
15. Hervé F, Ghinea N, Scherrmann JM (2008) CNS delivery via adsorptive transcytosis. AAPS J 10(3):455-472.
16. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ (2008) Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA 105(45):17356-17361.
17. Kolishetti N, et al. (2010) Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci USA 107(42): 17939-17944.
18. Godwin AK, et al. (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89(7):3070-3074.
19. Maris JM, Matthay KK (1999) Molecular biology of neuroblastoma. J Clin Oncol 17(7): 2264-2279. (Pubitemid 29318861)
20. Committee for the Update on the Guide for the Care and Use of Laboratory Animals (2011) Guide for the Care and Use of Laboratory Animals (The National Academies Press, Washington, DC), 8th Ed.